Microbial factories for recombinant pharmaceuticals
- 43k Downloads
Most of the hosts used to produce the 151 recombinant pharmaceuticals so far approved for human use by the Food and Drug Administration (FDA) and/or by the European Medicines Agency (EMEA) are microbial cells, either bacteria or yeast. This fact indicates that despite the diverse bottlenecks and obstacles that microbial systems pose to the efficient production of functional mammalian proteins, namely lack or unconventional post-translational modifications, proteolytic instability, poor solubility and activation of cell stress responses, among others, they represent convenient and powerful tools for recombinant protein production. The entering into the market of a progressively increasing number of protein drugs produced in non-microbial systems has not impaired the development of products obtained in microbial cells, proving the robustness of the microbial set of cellular systems (so far Escherichia coli and Saccharomyces cerevisae) developed for protein drug production. We summarize here the nature, properties and applications of all those pharmaceuticals and the relevant features of the current and potential producing hosts, in a comparative way.
KeywordsRecombinant Protein Bovine Spongiform Encephalopathy Human Growth Hormone Therapeutic Protein Insect Cell Line
absorption, distribution, metabolism, and excretion
baby hamster kidney cells
chinese hamster ovary cells
European Medicines Agency
Food and Drug Administration
Recombinant insulins approved for human use.
Modifications from natural
PB28K and KB29P
Rapid-acting insulin analogue
NB3K and KB29E
Rapid-acting insulin analogue
Rapid-acting insulin analogue
NA21G and 2 additional R in B chain
Long-acting insulin analogue
TB30del and myristic fatty acid attached to KB29 by acylation
Long-acting insulin analogue
On the other hand, the frequencies with which the different codons appear in E. coli genes are different from those occurring in human genes, and this is directly related to the abundance of specific tRNAs. Therefore, genes that contain codons rare for E. coli may be inefficiently expressed by this organism and cause premature termination of protein synthesis or amino acid misincorporation, thus reducing the yield of expected protein versions . This problem can be solved either by site-directed replacement of rare codons in the target gene by codons that are more frequently used in E. coli, or, alternatively, by the co-expression of the rare tRNAs (E. coli strains BL21 codon plus and Rosetta were designed for this purpose). In addition, initial methionine removal depends on the side chain of the penultimate amino acid of N-terminal in final recombinant proteins produced in E. coli although it can be efficiently removed using recombinant methionine aminopeptidase . Some mutant E. coli strains have been developed to promote disulfide bond formation (AD494, Origami, Rosetta-gami) and/or with reduced protease activity (BL21). As an additional technical obstacle, proteins larger than 60 kDa are inefficiently obtained in soluble forms in E. coli .
As it has been well documented, bacteria overproducing either eukaryotic or prokaryotic recombinant proteins are subjected to different stresses (essentially metabolic and conformational) . Under this situation, protein processing associated to cell stress responses might render non useless products, mainly because of lack of solubility, and many protein species deposit in high amounts as protein aggregates known as inclusion bodies (IBs) [22, 23, 24, 25]. By adjusting media composition, growth temperature, inducer concentration, promoter strength and plasmid copy number, variable amounts of the target protein can be forced to appear in the soluble form [26, 27], although unfortunately, many eukaryotic proteins are exclusively found trapped in IBs and seem to be resistant to process-based solubility enhancement. While IBs formed by enzymes can be efficient catalysers in enzymatic reactions [28, 29, 30, 31, 32], pharmaceutical proteins need, in contrast, to be dispersed as soluble entities to reach their targets at therapeutic doses. IBs essentially contain the recombinant protein in variable proportions (from 60 to more than 90%) and some contaminants as chaperones, DNA, RNA and lipids . Although stored protein can be released from IBs using denaturing conditions, in vitro refolding processes are not as effective as expected  and other expression systems should be tried. In some cases, recombinant proteins have been successfully purified from IBs as for example Betaferon  and insulin . However, for non integral membrane proteins, cytosolic and/or soluble protein domains, the probability of success is reasonably high and E. coli should be then considered as a promising expression system .
Production in yeast is usually approached when the target protein is not produced in a soluble form in the prokaryotic system or a specific PTM, essential for its biological activity, cannot be produced artificially on the purified product . Yeasts are as cost effective, fast and technically feasible as bacteria and high density cell cultures can also be reached in bioreactors. Even more, mutant strains that produce high amounts of heterologous protein are already available. Even though yeasts are able to perform many PTMs as O-linked glycosylation, phosphorylation, acetylation and acylation, the main pitfall of this expression system is related to N-linked glycosylation patterns which differ from higher eukaryotes, in which sugar side chains of high mannose content affect the serum half-life and immunogenicity of the final product. Although less studied than in bacteria, the production of recombinant proteins also triggers conformational stress responses and produced proteins fail sometimes to reach their native conformation. Recent insights about conformational stress, and in general, to cell responses to protein production in recombinant yeasts have been extensively reviewed elsewhere [21, 39, 40].
The approved protein products produced in yeast are obtained exclusively in Saccharomyces cerevisiae  and correspond to hormones (insulin, insulin analogues, non glycosylated human growth hormone somatotropin, glucagon), vaccines (hepatitis B virus surface antigen -in the formulation of 15 out of the 28 yeast derived products-) and virus-like particles (VLPs) of the major capsid protein L1 of human papillomavirus type 6, 11, 16 and 18, urate oxidase from Aspergillus flavus, granulocyte-macrophage colony stimulating factor, albumin, hirudin of Hirudo medicinalis and human platelets derived growth factor. As in the case of E. coli, most of the recombinant pharmaceuticals from yeast are addressed to either infectious diseases or endocrine, nutritional and metabolic disorders (Figure 2), being these therapeutic areas the most covered by microbial products. Interestingly, several yeast species other than S. cerevisiae are being explored as sources of biopharmaceuticals and other proteins of biomedical interest [21, 41]. In addition, current metabolic engineering approaches  and optimization of process procedures [43, 44] are dramatically expanding the potential of yeast species for improved production of recombinant proteins.
Insect cell lines
Cultured insect cells are used as hosts for recombinant baculovirus infections. The production of a recombinant viral vector for gene expression is time-consuming, the cell growth is slow when compared with former expression systems, the cost of growth medium is high and each protein batch preparation has to be obtained from fresh cells since viral infection is lethal. PTMs are also an important limitation of this expression system because of the simple non-syalated N-linked glycosylation which is translated in a rapid clearance from human sera . Although genetic engineering has been used to select transgenic insect cell lines (MIMIC™ from Invitrogen and SfSWT-3) expressing galactosyltransferase, N-acetylglucosaminyltransferases, syalic acid synthases and syaliltransferases genes [46, 47, 48] to obtain humanized complex N-linked glycosylation protein patterns, there are still unwanted toxicological issues that need to be overcome.
There is only one approved biopharmaceutical product containing recombinant proteins from infected insect cell line Hi Five, Cervarix, consisting on recombinant papillomavirus C-terminal truncated major capsid protein L1 types 16 and 18. Nonetheless, this expression system has been extensively used in structural studies since correctly folded eukaryotic proteins can be obtained in a secreted form in serum free media which enormously simplifies protein capture in purification protocols.
Hybridoma cell lines
Hybridomas are fusion cells of murine origin (B-cells and myeloma tumour cells) that are able to express specific monoclonal antibodies against a determined antigen, thus possessing therapeutic potential . Clone selection may account for the progressive enrichment of cells displaying a glycosylation profile with reduced potency and undesirable immunogenic reaction since the human immune system recognizes mouse antibodies as foreign.
Genetic engineering has been applied to obtain humanized monoclonal antibodies using either recombinant mammalian cells producing chimeric antibodies or genetically modified mice to produce human-like antibodies . One such product, Remicade, which binds tumour necrosis factor-alpha, is a pharmaceutical blockbuster used in the treatment of Crohn's disease.
Hamster cell lines
Most of the therapeutic proteins approved so far have been obtained using transgenic hamster cell lines, namely 49 in chinese hamster ovary cells (CHO) and 1 in baby hamster kidney cells (BHK) (Additional file 1). The main advantage of this expression system is that cells can be adapted to grow in suspension in serum free media (SFM), protein-free and chemically defined media . This fact increases the biosafety of final products reducing risk of introducing prions of bovine spongiform encephalopathy (BSE) from bovine serum albumin and of infectious variant Creutzfeldt-Jakob Disease (vCJD) from human serum albumin. In addition, recombinant products can be secreted into the chemical defined media, which simplifies both upstream and downstream purification process . PTMs in this expression system are almost the same as in human cell lines, although some concerns about comparability in the glycosylation pattern have arisen when comparing different batches of the same manufacturer product and biosimilars . Further development of chemically defined media and fine description of growth conditions would help to overcome this issue.
Human cell lines
In the recent years, three therapeutic proteins produced in human cell lines have been approved, namely Dynepo-erithropoietin, Elaprase-irudonate-2-sulfatase and Replagal-alfa-galactosidase A. These products are fully glycosylated human proteins, so this expression system should be addressed when heavily glycosylation is needed. In general, recombinant biopharmaceuticals obtained from mammalian cells cover a wider spectrum of pathological conditions than those obtained from microbes, and the distribution of applications is less biased than when observing products from E. coli or S. cerevisae (Figure 2).
Transgenic animals (avian and mammals), have been successfully used for the production of recombinant proteins secreted into egg white and milk respectively. Protein production using transgenic farm animals supposes a great biotechnological challenge in terms of safety concerns such as transmission of infectious diseases (including viral and prion infections) or adverse allergenic, immunogenic and autoimmune responses. In 2006, ATryn was the first and so far single approved rDNA biopharmaceutical using transgenic animals and validated manufacturer technology platform. It contains human antithrombin (432 amino acids) with 15% glycosylated moieties and is secreted into the milk of transgenic goats. Another product obtained from the milk of transgenic rabbits (Rhucin) has been recently denied for its approval by the EMEA although more tests of repeated treatment are underway to try again its approval. Despite such limited progress, if pharmacovigilance after patient treatment does not reveal any adverse side effects, we might envisage, in the next years, an increase in the approval rate of recombinant protein products from transgenic animal origin.
Alternative, non microbial systems for forthcoming products
As previously discussed, recombinant DNA biopharmaceuticals obtained from bacterial, yeast or mammalian cell culture bioreactors are quite effective as therapeutic agents although production costs are relatively high. One way to address the economic-cost benefit hurdle is through the use of transgenic organisms to manufacture biopharmaceuticals. Biopharming would dramatically reduce the cost of recombinant therapeutic proteins not only in the initial construction of production facilities but also the scale-up process and the final recombinant protein yield. Nonetheless, the fact that regulatory guidelines are being developed as the same time that the establishment of protein production processes is creating uncertainty within biotechnological companies to fulfil drug administration requirements.
Transgenic plants have been used as recombinant protein producers for research and diagnostic uses due to the advantageous low cost of cultivation, high mass production, flexible scale-up, lack of human pathogens and addition of eukaryotic PTMs. The first recombinant protein product obtained from transgenic tobacco was human growth hormone  and since then, many other products have been obtained (including antibodies, the surface antigen of the Hepatitis-B-Virus, industrial enzymes and milk proteins). Again, the main disadvantage is related to the plant specific PMTs introduced in recombinant proteins which produce adverse immune responses. Moreover, the possibility to spread the proteins in open fields and the negative public perception of the transgenic plants precludes the use of plants as an attractive expression system of therapeutic proteins.
Host comparative trends in rDNA biopharmaceutical approval
Interestingly, a plateau in the rate of rDNA drug approval during the last 2–3 years is becoming perceivable, irrespective of the production system (Figure 3). Although it might be observed as a transient event, this fact seems instead to indicate that the current production systems could be near to the exhaustion regarding their ability to hold the production of complex proteins, protein complexes or the so-called difficult-to-express proteins. Desirably, recent insights about system's biology of recombinant cells and hosts, and specially, arising novel concepts on recombinant protein quality [54, 55, 56] and host stress responses  would enlarge the possibilities for metabolic and process engineering aiming to the economically feasible production of new, more complex drugs. Indeed, pushed by fast advances in molecular medicine the pharmaceutical industry is urgently demanding improved production systems and novel and cheaper drugs.
Conclusions and future prospects
Overcoming the biological and methodological obstacles posed by cell factories to the production or rDNA pharmaceuticals is a main challenge in the further development of protein-based molecular medicine. Recombinant DNA technologies might have exhausted conventional cell factories and new production systems need to be deeply explored and incorporated into the production pipeline. On the other hand, a more profound comprehension of host cell physiology and stress responses to protein production would necessary offer improved tools (either at genetic, metabolic or system levels) to favour high yield and high quality protein production. Apart from the expected incorporation of unusual mammalian hosts such as transgenic animals or plants, microbial cells appear as extremely robust and convenient hosts, and gaining knowledge about the biological aspects of protein production would hopefully enhance the performance of such hosts beyond the current apparent limitations. In this regard, not only commonly used bacteria and yeasts but unconventional strains or species are observed as promising cell factories for forthcoming recombinant drugs. Their incorporation into productive processes for human pharmaceuticals would hopefully push the trend of marketed products and fulfil the increasing demands of the pharmacological industry.
The authors acknowledge the support of MEC, AGAUR and UAB to their research on protein drug development and delivery through grants BIO2007-61194 to AV (MEC), 2005SGR-00956 to AV (AGAUR) and EME2007-08 to NFM (UAB). We also appreciate the support of CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN, promoted by ISCIII), Spain. AV received an ICREA ACADEMIA award from ICREA (Generalitat de Catalunya).
- 2.Human insulin receives FDA approval. FDA Drug Bull. 1982, 12: 18-19.Google Scholar
- 3.Redwan e: Cumulative updating of approved biopharmaceuticals. Hum Antibodies. 2007, 16: 137-158.Google Scholar
- 18.Makrides SC: Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol Rev. 1996, 60: 512-538.Google Scholar
- 20.Gräslund S, Nordlund P, Weigelt J, Hallberg BM, Bray J, Gileadi O, Knapp S, Oppermann U, Arrowsmith C, Hui R, Ming J, dhe-Paganon S, Park HW, Savchenko A, Yee A, Edwards A, Vincentelli R, Cambillau C, Kim R, Kim SH, Rao Z, Shi Y, Terwilliger TC, Kim CY, Hung LW, Waldo GS, Peleg Y, Albeck S, Unger T, Dym O, et al: Protein production and purification. Nat Methods. 2008, 5: 135-146.CrossRefGoogle Scholar
- 21.Gasser B, Saloheimo M, Rinas U, Dragosits M, Rodríguez-Carmona E, Baumann K, Giuliani M, Parrilli E, Branduardi P, Lang C, Porro D, Ferrer P, Tutino ML, Mattanovich D, Villaverde A: Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact. 2008, 7: 11-CrossRefGoogle Scholar
- 22.Prouty WF, Karnovsky MJ, Goldberg AL: Degradation of abnormal proteins in Escherichia coli. Formation of protein inclusions in cells exposed to amino acid analogs. J Biol Chem. 1975, 250: 1112-1122.Google Scholar
- 33.Neubauer P, Fahnert B, Lilie h, Villaverde A: Protein inclusion bodies in recombinant bacteria. In Inclusions in Prokaryotes. Microbiology Monographs. Edited by: Shively JM. 2006, 237-292. SpringerGoogle Scholar
- 35.Lin L: Betaseron. Dev Biol Stand. 1998, 96: 97-104.Google Scholar
- 37.RCSB Protein Data Bank. 2008, http://www.rcsb.org
- 38.Target DB. 2008, http://targetdb.pdb.org/
- 43.Gurramkonda C, Adnan A, Gäbel T, Lünsdorf H, Ross A, Nemani SK, Swaminathan S, Khanna N, Rinas U: Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of Hepatitis B surface antigen. Microb Cell Fact. 2009, 8: 13-CrossRefGoogle Scholar
- 49.Nissim A, Chernajovsky Y: Historical development of monoclonal antibody therapeutics. Handb Exp Pharmacol. 2008, 3-18.Google Scholar
- 50.Bleckwenn NA, Shiloach J: Large-scale cell culture. Curr Protoc Immunol. 2004, Appendix 1: AppendixGoogle Scholar
- 52.Yuen CT, Storring PL, Tiplady RJ, Izquierdo M, Wait R, Gee CK, Gerson P, Lloyd P, Cremata JA: Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures. Br J Haematol. 2003, 121: 511-526.CrossRefGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.